ArticleOncotarget2017

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.

Dimpy Koul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.